157 related articles for article (PubMed ID: 31848493)
21. Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still's disease.
Wakabayashi K; Inokuma S; Matsubara E; Onishi K; Asashima H; Nakachi S; Hagiwara K
Clin Rheumatol; 2013 Jul; 32(7):999-1005. PubMed ID: 23504210
[TBL] [Abstract][Full Text] [Related]
22. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases.
Maruyama J; Inokuma S
J Rheumatol; 2010 May; 37(5):967-73. PubMed ID: 20231207
[TBL] [Abstract][Full Text] [Related]
23. Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients.
Ruscitti P; Rago C; Breda L; Cipriani P; Liakouli V; Berardicurti O; Carubbi F; Di Battista C; Verrotti A; Giacomelli R
Clin Rheumatol; 2017 Dec; 36(12):2839-2845. PubMed ID: 28914368
[TBL] [Abstract][Full Text] [Related]
24. [The clinical characteristics of macrophage activation syndrome secondary to systemic lupus erythematosus].
Jiang N; Li MT; Wu D; Zeng XF
Zhonghua Nei Ke Za Zhi; 2016 Nov; 55(11):840-844. PubMed ID: 27801337
[No Abstract] [Full Text] [Related]
25. Epidemiological study of adult-onset Still's disease using a Japanese administrative database.
Sakata N; Shimizu S; Hirano F; Fushimi K
Rheumatol Int; 2016 Oct; 36(10):1399-405. PubMed ID: 27502500
[TBL] [Abstract][Full Text] [Related]
26. Macrophage activation syndrome in neonates born to mothers with adult-onset Still's disease: Perinatal effect of maternal IL-18.
Shimizu M; Kizawa T; Kato R; Suzuki T; Yachie A
Clin Immunol; 2019 Oct; 207():36-39. PubMed ID: 31299380
[TBL] [Abstract][Full Text] [Related]
27. In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome.
Ahn SS; Yoo BW; Jung SM; Lee SW; Park YB; Song JJ
Semin Arthritis Rheum; 2017 Oct; 47(2):216-221. PubMed ID: 28268026
[TBL] [Abstract][Full Text] [Related]
28. The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still's disease.
Chen DY; Chen YM; Lin CC; Hsieh CW; Wu YC; Hung WT; Chen HH; Lan JL
BMC Musculoskelet Disord; 2015 May; 16():111. PubMed ID: 25956266
[TBL] [Abstract][Full Text] [Related]
29. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort.
Kalyoncu U; Solmaz D; Emmungil H; Yazici A; Kasifoglu T; Kimyon G; Balkarli A; Bes C; Ozmen M; Alibaz-Oner F; Erten S; Cagatay Y; Cetin GY; Yilmaz S; Yildiz F; Pamuk ON; Kucuksahin O; Kilic L; Yazisiz V; Karadag O; Koca SS; Hayran M; Akar S; Aksu K; Akkoc N; Keser G; Gonullu E; Kisacik B; Onat AM; Soy M; Inanc N; Direskeneli H; Sayarlioglu M; Erken E; Turgay M; Cefle A; Ertenli I; Pay S
J Autoimmun; 2016 May; 69():59-63. PubMed ID: 26970681
[TBL] [Abstract][Full Text] [Related]
30. Macrophage activation syndrome associated with adult-onset Still's disease.
Iwamoto M
Nihon Rinsho Meneki Gakkai Kaishi; 2007 Dec; 30(6):428-31. PubMed ID: 18174671
[TBL] [Abstract][Full Text] [Related]
31. Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease.
Jung SY; Park YB; Ha YJ; Lee KH; Lee SK
J Rheumatol; 2010 May; 37(5):1029-34. PubMed ID: 20231196
[TBL] [Abstract][Full Text] [Related]
32. Clinical features of macrophage activation syndrome in the adult northern Chinese population.
Li X; Qu B; Nie Y; Zhu G; Li W; Mu F
Lupus; 2014 Jul; 23(8):785-92. PubMed ID: 24682586
[TBL] [Abstract][Full Text] [Related]
33. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.
Minoia F; Davì S; Horne A; Demirkaya E; Bovis F; Li C; Lehmberg K; Weitzman S; Insalaco A; Wouters C; Shenoi S; Espada G; Ozen S; Anton J; Khubchandani R; Russo R; Pal P; Kasapcopur O; Miettunen P; Maritsi D; Merino R; Shakoory B; Alessio M; Chasnyk V; Sanner H; Gao YJ; Huasong Z; Kitoh T; Avcin T; Fischbach M; Frosch M; Grom A; Huber A; Jelusic M; Sawhney S; Uziel Y; Ruperto N; Martini A; Cron RQ; Ravelli A; ; ; ;
Arthritis Rheumatol; 2014 Nov; 66(11):3160-9. PubMed ID: 25077692
[TBL] [Abstract][Full Text] [Related]
34. Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.
Cohen EM; D'Silva K; Kreps D; Son MB; Costenbader KH
Lupus; 2018 Jun; 27(7):1065-1071. PubMed ID: 29451069
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of emapalumab in macrophage activation syndrome.
De Benedetti F; Grom AA; Brogan PA; Bracaglia C; Pardeo M; Marucci G; Eleftheriou D; Papadopoulou C; Schulert GS; Quartier P; Antón J; Laveille C; Frederiksen R; Asnaghi V; Ballabio M; Jacqmin P; de Min C
Ann Rheum Dis; 2023 Jun; 82(6):857-865. PubMed ID: 37001971
[TBL] [Abstract][Full Text] [Related]
36. Macrophage Activation Syndrome Associated With Adult Onset Still's Disease.
Gulzar M; Sabir A; Hamdani MA; Saadia A
J Ayub Med Coll Abbottabad; 2018; 30(2):289-292. PubMed ID: 29938438
[TBL] [Abstract][Full Text] [Related]
37. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China.
Zou LX; Zhu Y; Sun L; Ma HH; Yang SR; Zeng HS; Xiao JH; Yu HG; Guo L; Xu YP; Lu MP
World J Pediatr; 2020 Feb; 16(1):89-98. PubMed ID: 31612427
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients.
Ortiz-Sanjuán F; Blanco R; Calvo-Rio V; Narvaez J; Rubio Romero E; Olivé A; Castañeda S; Gallego Flores A; Hernández MV; Mata C; Ros Vilamajo I; Sifuentes Giraldo WA; Caracuel MA; Freire M; Gómez Arango C; Llobet J; Manrique Arija S; Marras C; Moll-Tuduri C; Plasencia-Rodriguez C; Roselló R; Urruticoechea A; Velloso-Feijoo ML; Del Blanco J; González-Vela MC; Rueda-Gotor J; Pina T; Loricera J; González-Gay MA
Arthritis Rheumatol; 2014 Jun; 66(6):1659-65. PubMed ID: 24515813
[TBL] [Abstract][Full Text] [Related]
39. Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease.
Ruscitti P; Cipriani P; Di Benedetto P; Ciccia F; Liakouli V; Carubbi F; Berardicurti O; Rizzo A; Triolo G; Giacomelli R
Autoimmun Rev; 2015 May; 14(5):429-37. PubMed ID: 25599955
[TBL] [Abstract][Full Text] [Related]
40. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome.
Kobayashi M; Takahashi Y; Yamashita H; Kaneko H; Mimori A
Mod Rheumatol; 2011 Feb; 21(1):92-6. PubMed ID: 20737186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
